Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yipanzhu is a topical pharmaceutical preparation developed by Wuhan Tonghua Technology Development Co., Ltd., primarily indicated for the treatment of acute soft tissue injuries such as sprains, strains, and contusions. It is a Chinese Patent Medicine (CPM) derived from the extract of the medicinal plant *Sarcopyramis nepalensis* Wall., which is traditionally valued in Chinese medicine for its ability to resolve blood stasis, reduce swelling, and alleviate pain. Formulated as a spray, Yipanzhu is designed for rapid local application to the affected area, where it works to improve microcirculation and modulate inflammatory responses, thereby accelerating the resolution of hematomas and reducing localized pain and inflammation associated with traumatic injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yipanzhu.